Apolipoprotein A5 gene variants and the risk of coronary heart disease: A case‑control study and meta‑analysis

Zhou,Jianqing; Xu,Limin; Huang,Rong  Stephanie; Huang,Yi; Le,Yanping; Jiang,Danjie; Yang,Xi; Xu,Weifeng; Huang,Xiaoyan; Dong,Changzheng; Ye,Meng; Lian,Jiangfang; Duan,Shiwei

doi:10.3892/mmr.2013.1642

Apolipoprotein A5 gene variants and the risk of coronary heart disease: A case‑control study and meta‑analysis

Authors:
- Jianqing Zhou
- Limin Xu
- Rong Stephanie Huang
- Yi Huang
- Yanping Le
- Danjie Jiang
- Xi Yang
- Weifeng Xu
- Xiaoyan Huang
- Changzheng Dong
- Meng Ye
- Jiangfang Lian
- Shiwei Duan
View Affiliations

Affiliations: Ningbo Medical Center, Lihuili Hospital, Ningbo University, Ningbo, Zhejiang 315041, P.R. China, Zhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, Zhejiang 315211, P.R. China, Department of Medicine, University of Chicago, Chicago, IL 60637, USA
Published online on: August 16, 2013 https://doi.org/10.3892/mmr.2013.1642
Pages: 1175-1182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that apolipoprotein A5 (APOA5) gene variants are genetic determinants of the concentration of triglycerides, which are a known risk factor for coronary heart disease (CHD). Using the standardized coronary angiography method, 290 CHD patients and 198 non‑CHD controls were recruited from Ningbo Lihuili Hospital. In addition, 331 unrelated healthy volunteers were recruited as healthy controls from Ningbo Ximen Community residents. Three variants of the APOA5 gene, S19W, ‑1131T>C and 553G>T, were analyzed for their association with CHD. Under a dominant inheritance model, ‑1131CT>C was shown to be a CHD risk factor (P=0.030; OR, 1.422; 95% CI, 1.036‑1.952). The single nucleotide polymorphism, 553G>T, was found to correlate with the severity of CHD in males (P=0.032). Meta‑analysis showed that ‑1131T>C was significantly associated with CHD (P<0.0001). By contrast, negative correlations with CHD were observed for S19W and 553G>T. In the present case‑control study, APOA5 gene variants were not found to correlate with the risk of CHD in the populations studied; however, ‑1131CT>C was shown to be a CHD risk factor under a dominant inheritance model. Meta‑analysis showed a significant contribution of ‑1131T>C to the risk of CHD, implying an ethnic difference in APOA5 gene variants.

View Figures

View References

1	Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C and Sacks FM: Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 106:757–763. 2010. View Article : Google Scholar
2	Maász A, Kisfali P, Horvatovich K, et al: Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res. 13:243–247. 2007.PubMed/NCBI
3	Evans D, Aberle J and Beil FU: Resequencing the apolipoprotein A5 (APOA5) gene in patients with various forms of hypertriglyceridemia. Atherosclerosis. 219:715–720. 2011. View Article : Google Scholar : PubMed/NCBI
4	Peden JF and Farrall M: Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour. Hum Mol Genet. 20:R198–R205. 2011. View Article : Google Scholar : PubMed/NCBI
5	Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM and Rubin EM: An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294:169–173. 2001. View Article : Google Scholar : PubMed/NCBI
6	Martinelli N, Trabetti E, Bassi A, Girelli D, Friso S, Pizzolo F, Sandri M, Malerba G, Pignatti PF, Corrocher R and Olivieri O: The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis. 191:409–417. 2007.
7	Szalai C, Keszei M, Duba J, Prohászka Z, Kozma GT, Császár A, Balogh S, Almássy Z, Fust G and Czinner A: Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis. 173:109–114. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu H, Zhang S, Lin J, et al: Association between DNA variant sites in the apolipoprotein A5 gene and coronary heart disease in Chinese. Metabolism. 54:568–572. 2005. View Article : Google Scholar : PubMed/NCBI
9	Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Sarwar N, Sandhu MS, Ricketts SL, et al: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 375:1634–1639. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yu Y, Xue L and Zhao CY: Study on polymorphism in the apolipoprotein A5 gene in patients with premature coronary heart disease. Beijing Da Xue Xue Bao. 39:576–580. 2007.(In Chinese).
11	Li X, Yao C, Song M, Ma J, Ning H and Hu B: The relationship between the polymorphism of apolipoprotein A5 gene 56C>G and the level of serum triglyceride. Ningxia Yi Xue Za Zhi. 9:643–645. 2006.(In Chinese).
12	Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X and Ordovas JM: The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res. 44:2365–2373. 2003. View Article : Google Scholar
13	Kao JT, Wen HC, Chien KL, Hsu HC and Lin SW: A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet. 12:2533–2539. 2003. View Article : Google Scholar : PubMed/NCBI
14	Tang Y, Sun P, Guo D, Ferro A, Ji Y, Chen Q and Fan L: A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis. 185:433–437. 2006.PubMed/NCBI
15	Prochaska CL, Picheth G, Anghebem-Oliveira MI, Costantini CO, de Souza EM, Pedrosa FO and Scartezini M: The polymorphisms -1131T>C and the S19W of the APOA5 gene are not associated with coronary artery disease in a Brazilian population. Clin Chem Lab Med. 48:419–422. 2010.
16	Maász A, Kisfali P, Szolnoki Z, Hadarits F and Melegh B: Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke. J Neurol. 255:649–654. 2008.PubMed/NCBI
17	No authors listed. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation. 59:607–609. 1979. View Article : Google Scholar
18	Nikus KC: Chapter 4: Coranory angiography. Multimodal Imaging: Principles and Clinical Applications: Section I: Current methods and their applications for cardiovascular multimodal imaging. Pahlm O and Wagner GS: McGraw-Hill Medical; New York, NY: pp. 752011
19	Higgs ZC, Macafee DA, Braithwaite BD and Maxwell-Armstrong CA: The Seldinger technique: 50 years on. Lancet. 366:1407–1409. 2005.PubMed/NCBI
20	Gabriel S, Ziaugra L and Tabbaa D: SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. (Suppl 60): 2.12.1–2.12.18. 2009.
21	Excoffier L and Lischer HE: Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour. 10:564–567. 2010. View Article : Google Scholar
22	Sham PC and Curtis D: Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 59(Pt 1): 97–105. 1995. View Article : Google Scholar : PubMed/NCBI
23	Dupont WD and Plummer WD Jr: Power and sample size calculations. A review and computer program. Control Clin Trials. 11:116–128. 1990. View Article : Google Scholar : PubMed/NCBI
24	Aberle J, Evans D, Beil FU and Seedorf U: A polymorphism in the apolipoprotein A5 gene is associated with weight loss after short-term diet. Clin Genet. 68:152–154. 2005. View Article : Google Scholar : PubMed/NCBI
25	Liu HK, Wang CT, Zhang SZ, et al: Association of APOA5 gene single nucleotide polymorphism with levels of lipids and coronary heart disease in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 21:335–338. 2004.(In Chinese).
26	Yuan S, Ma YT, Xie X, Yang YN, Fu ZY, Ma X, Li XM, Xiang Y, Liu F and Chen BD: Association of apolipoprotein A5 gene polymorphism with coronary heart disease in Uygur population of Xinjiang. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 28:73–77. 2011.(In Chinese).
27	Hubacek JA, Wang WW, Skodová Z, Adámková V, Vráblík M, Horínek A, Stulc T, Ceska R and Talmud PJ: APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. Clin Chem Lab Med. 46:773–777. 2008.PubMed/NCBI
28	Eichenbaum-Voline S, Olivier M, Jones EL, et al: Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 24:167–174. 2004. View Article : Google Scholar
29	Yuan S, Ma YT, Xie X, Yang YN, Fu ZY, Ma X, Li XM, Liu F and Chen BD: Association between apolipoprotein A5 gene polymorphism and coronary heart disease in the Han population from Xinjiang. Zhonghua Liu Xing Bing Xue Za Zhi. 32:51–54. 2011.(In Chinese).
30	Song KH, Yu SG, Cha S and Kim JY: Association of the Apolipoprotein A5 gene -1131T>C polymorphism with serum lipids in Korean subjects: impact of Sasang constitution. Evid Based Complement Alternat Med. 2012:5983942012.
31	Ramakrishnan L, Sachdev HS, Sharma M, et al: Relationship of APOA5, PPARγ and HL gene variants with serial changes in childhood body mass index and coronary artery disease risk factors in young adulthood. Lipids Health Dis. 10:682011.
32	Yan SK, Cheng XQ, Song YH, Xiao XH, Bi N and Chen BS: Apolipoprotein A5 gene polymorphism -1131T→C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese. Clin Chem Lab Med. 43:607–612. 2005.
33	Havasi V, Szolnoki Z, Talián G, et al: Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci. 29:177–183. 2006. View Article : Google Scholar
34	Maasz A, Kisfali P, Jaromi L, Horvatovich K, Szolnoki Z, Csongei V, Safrany E, Sipeky C, Hadarits F and Melegh B: Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. Circ J. 72:1065–1070. 2008.
35	Jang Y, Paik JK, Hyun YJ, Chae JS, Kim JY, Choi JR, Lee SH, Shin DJ, Ordovas JM and Lee JH: The apolipoprotein A5 -1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta. 402:83–87. 2009.
36	Ruiz-Narváez EA, Yang Y, Nakanishi Y, Kirchdorfer J and Campos H: APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res. 46:2605–2613. 2005.PubMed/NCBI
37	Hubacek JA, Skodová Z, Adámková V, Lánská V and Poledne R: The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet. 65:126–130. 2004.
38	Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P and Helbecque N: Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int J Cardiol. 106:152–156. 2006. View Article : Google Scholar : PubMed/NCBI
39	Dorfmeister B, Zeng WW, Dichlberger A, et al: Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol. 28:1866–1871. 2008. View Article : Google Scholar
40	Johansen CT, Kathiresan S and Hegele RA: Genetic determinants of plasma triglycerides. J Lipid Res. 52:189–206. 2011. View Article : Google Scholar : PubMed/NCBI
41	Lim S, Park YM, Sakuma I and Koh KK: How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol. 166:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
42	Hokanson JE and Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:213–219. 1996. View Article : Google Scholar
43	Merkel M and Heeren J: Give me A5 for lipoprotein hydrolysis! J Clin Invest. 115:2694–2696. 2005.PubMed/NCBI
44	Li G, Wang JY, Yan S, Zhang LJ, Xue H, Zeng WW, Wu G and Chen BS: The relationship between the polymorphism of apolipoprotein A5 gene 56C→G and the levels of serum triglyceride. Zhonggua Dong Mai Ying Hua Za Zhi. 5:574–576. 2004.(In Chinese).